

CA LAPA 250

(Lapatinib ditosylate 250 mg Tab)



Breast Cancer

In treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2.
In combination with capecitabine.

For the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the HER2. (in combination with letrozole).

The dual tyrosine kinase inhibitor

CA LAPA 1250 mg PO qDay on Days 1-21 continuously in combination with Capecitabine (2000 mg/m²/day PO divided q12hr) on Days 1-14 in a repeating 21-day cycle.

Dosage:

Hormone-positive and HER2-positive advanced breast cancer
CA LAPA 1500 mg PO qDay administered continuously in combination with letrozole 2.5 mg PO qDay.



112,113,114 Crescent Business Park,
Sakinaka Telephone exchange Lane.
Andheri (East). Mumbai 400 072



www.mxmhealthcare.com
assist@mxmhealthcare.com
+91 22 4801 6166 / +91 22 4616 6610